RGD-modified angiogenesis inhibitor HM-3 dose: Dual function during cancer treatment

Bioconjugate Chemistry

Volumn 22, Issue 7, 2011, Pages 1386-1393

  Xu, Hanmei ^a   Pan, Li ^a   Ren, Yinling ^a   Yang, Yongjing ^a   Huang, Xiaofeng ^b   Liu, Zhendong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DOSAGE; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTICANCER ACTIVITIES; DUAL FUNCTION; HIGH DOSE; IN-VITRO; LOW DOSE; MICROARRAY ANALYSIS; TUMOR METASTASIS; TUMORIGENESIS; VITRO AND IN VIVO;

DISEASES;

ANGIOGENESIS INHIBITOR; HM 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PACLITAXEL; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN;

EID: 79960607839     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc2000929     Document Type: Article

References (12)

1. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350, 2335-42 (Pubitemid 38702844)
2. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., and Davidson, N. E. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N. Engl. J. Med. 357, 2666-76
3. Demetri, G. D., Van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., Desai, J., Fletcher, C. D., George, S., Bello, C. L., Huang, X., Baum, C. M., and Casali, P. G. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial Lancet 368, 1329-38 (Pubitemid 44528723)
4. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., and Rini, B. I. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J. Clin. Oncol. 24, 16-24 (Pubitemid 46630489)
5. Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J. Y., Lathia, C., Schwartz, B., Taylor, I., Moscovici, M., and Saltz, L. B. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J. Clin. Oncol. 24, 4293-300 (Pubitemid 46630787)
6. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell. 15, 232-9
7. Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell. 15, 220-31
8. Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., Davidoff, A., Huber, J., Hicklin, D. J., and Kerbel, R. S. (2004) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies Cancer Res. 64, 6616-25 (Pubitemid 39297922)
9. Xu, H. M., Yin, R. T., Chen, L. Sh., Sami, S., Huang, X. F., Wang, M., Fang, H. Sh., and Wang, Y. (2008) An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo Bioconjugate Chem. 19, 1980-6
10. Folkman, J. and Kalluri, R. (2004) Cancer without disease Nature 427, 787 (Pubitemid 38297724)
11. Christensen, J. G. (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities Ann. Oncol. 18, x3-x10
12. Pietras, K. and Hanahan, D. (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23, 939-52 (Pubitemid 46202314)